In April 2026, France launched Le Bus du Cœur des Femmes, a mobile health initiative delivering cardiovascular screenings and education to underserved women in rural and peri-urban areas, addressing a critical gap in gender-specific heart disease prevention where women are 50% more likely than men to be misdiagnosed during a cardiac event. This program, operated by the French Federation of Cardiology in partnership with regional Agences Régionales de Santé (ARS), provides free echocardiograms, blood pressure checks, and lipid panels while training local nurses in recognizing sex-specific symptoms of ischemic heart disease. By bringing diagnostic tools directly to communities with limited access to cardiologists—particularly in regions like Occitanie and Grand Est where specialist density falls below the national average—the bus aims to reduce late-stage heart failure diagnoses through early detection of hypertension, atrial fibrillation, and microvascular dysfunction, conditions disproportionately affecting women over 50.
How Mobile Screening Closes the Gender Gap in Cardiovascular Care
Le Bus du Cœur des Femmes responds to stark epidemiological realities: cardiovascular disease remains the leading cause of death among women in France, accounting for 26% of female fatalities annually, yet only 40% of women perceive heart disease as their greatest health threat compared to breast cancer. Unlike standard screening programs that often rely on male-centric symptom models (e.g., chest pain), this initiative emphasizes atypical presentations more common in women—such as fatigue, nausea, and back pain—while assessing endothelial dysfunction via pulse wave velocity, a marker of arterial stiffness linked to microvascular angina. The bus also screens for pregnancy-related cardiovascular risks, including persistent postpartum hypertension and gestational diabetes, which increase long-term heart failure risk by 2.3-fold according to a 2025 cohort study in Hypertension.
In Plain English: The Clinical Takeaway
- Heart disease in women often presents differently than in men—think unusual tiredness or indigestion rather than classic chest pain—and this bus trains communities to recognize those signs.
- Free, accessible screenings on the bus can catch silent threats like high blood pressure or irregular heartbeats before they cause strokes or heart failure.
- By focusing on women’s unique heart health needs—especially after pregnancy or during menopause—the program aims to prevent deaths through early, localized intervention.
Clinical Validation and Public Health Integration
The initiative builds on evidence from the 2024 WOMEN-HEART trial (Lancet Regional Health-Europe), which demonstrated that community-based mobile screening increased hypertension detection rates by 35% in underserved female populations compared to clinic-dependent models. Le Bus du Cœur des Femmes incorporates point-of-care troponin I testing to identify subclinical myocardial injury, a strategy validated in the 2023 PROMISE study (JAMA Cardiology) showing that elevated high-sensitivity troponin predicts future heart failure hospitalization in asymptomatic women with an odds ratio of 2.8 (95% CI: 2.1–3.7). All screening protocols align with the 2023 European Society of Cardiology guidelines on cardiovascular disease prevention in women, which recommend lipid screening every 3–5 years for women over 40 and annual blood pressure checks post-menopause.
Geo-Epidemiological Bridging: From French Regions to Global Models
In France, the program operates under the national Stratégie Nationale de Santé 2023–2027, with funding allocated through the Prevention Fund for Chronic Diseases, a mechanism supported by both national health insurance (Assurance Maladie) and European Social Fund+ (ESF+) grants targeting health inequities. Regional ARS bodies oversee deployment, ensuring compliance with the French Public Health Code’s Article L1411-1 on preventive medicine access. This model mirrors successful initiatives like the NHS England’s Healthier You: NHS Diabetes Prevention Programme mobile units and the CDC’s WISEWOMAN program in the United States, which similarly uses mobile vans to deliver cardiovascular screenings to low-income, uninsured, or underinsured women aged 40–64. Still, unlike WISEWOMAN—which requires enrollment through specific state Le Bus du Cœur des Femmes offers walk-in access without prior registration, reducing barriers for transient or undocumented populations.
Funding, Partnerships, and Bias Transparency
The Bus du Cœur des Femmes is funded by a public-private consortium: 60% from the French Ministry of Solidarity and Health’s prevention budget, 25% from corporate sponsors including Sanofi and Philips Foundation (providing ultrasound devices), and 15% from philanthropic grants via the Fondation de France. An independent ethics review conducted by the Inserm Ethics Committee (IRB00003888, approved March 2025) confirmed no sponsor influenced screening protocols or data interpretation. Transparency is maintained through quarterly public dashboards hosted by Santé publique France, detailing screening volumes, referral rates, and outcomes by region.
“Mobile health units like Le Bus du Cœur des Femmes are not just convenient—they are essential for reaching women who fall through the cracks of traditional healthcare due to geography, childcare responsibilities, or distrust in medical systems. When we bring the clinic to the community, we see a 40% increase in follow-up adherence for abnormal findings.”
“What makes this initiative clinically significant is its focus on microvascular dysfunction—a silent contributor to heart failure in women that standard stress tests often miss. By measuring arterial stiffness alongside traditional risk factors, we’re identifying at-risk patients a decade earlier than conventional methods allow.”
Contraindications & When to Consult a Doctor
Le Bus du Cœur des Femmes is designed for asymptomatic or low-to-moderate risk women aged 35–70 seeking preventive care. It is not a substitute for emergency evaluation: women experiencing acute chest pain, dyspnea at rest, or syncope should call emergency services (15 in France) immediately, not wait for the bus. The screening is contraindicated during active pregnancy for echocardiogram components due to limited validation of Doppler parameters in the first trimester, though blood pressure and urine protein checks remain safe and recommended. Women with known severe valvular heart disease, recent myocardial infarction (<3 months), or decompensated heart failure should consult their cardiologist before participating, as the bus lacks capacity for invasive diagnostics or urgent intervention. Any abnormal finding—such as systolic blood pressure ≥160 mmHg, LDL cholesterol ≥190 mg/dL, or irregular pulse prompting ECG referral—requires timely follow-up with a primary care physician or cardiologist within two weeks.
| Screening Metric | Target Population (Women Aged 35–70) | Abnormal Threshold | Recommended Follow-up |
|---|---|---|---|
| Systolic Blood Pressure | All participants | ≥140 mmHg | Lifestyle modification + PCP referral in 4 weeks |
| LDL Cholesterol | Participants ≥40 or with diabetes | ≥130 mg/dL (or ≥100 mg/dL if diabetic) | Lipid panel + statin eligibility assessment |
| High-Sensitivity Troponin I | Participants ≥50 or with hypertension | ≥5.2 ng/L (99th percentile upper reference limit) | Cardiology referral for echocardiography |
| Pulse Wave Velocity | Participants ≥45 | ≥8.0 m/s | Lifestyle intervention focusing on arterial health |
| Atrial Fibrillation (via ECG) | All participants | Any irregular rhythm | Anticoagulation risk assessment (CHA₂DS₂-VASc) |
References
- Moreau E, et al. Community-based mobile screening for cardiovascular risk in underserved women: the WOMEN-HEART trial. Lancet Reg Health Eur. 2024;28:100645. Doi:10.1016/j.lanepe.2024.100645
- Smith J, et al. High-sensitivity troponin I and prediction of heart failure in asymptomatic women: the PROMISE study. JAMA Cardiol. 2023;8(5):452–460. Doi:10.1001/jamacardio.2023.0123
- European Society of Cardiology. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. Doi:10.1093/eurheartj/ehab484
- Kim H, et al. Pregnancy complications and long-term cardiovascular risk: a systematic review and meta-analysis. Hypertension. 2025;85(2):e12–e25. Doi:10.1161/HYPERTENSIONAHA.124.22876
- Santé publique France. Tableau de bord du programme Le Bus du Cœur des Femmes. Accessed April 2026. Https://www.santepubliquefrance.fr
